On August
27, Hubei Guangji Pharmaceutical Co.,Ltd. (Guangji Pharmaceutical) announced
that its subsidiary, Guangji Pharmaceutical Mengzhou Co.,Ltd. (Guangji Mengzhou),
has returned to normal production after an one-month overhaul starting from
August 1, 2019. In spite of the fact that all production was suspended during
the overhaul, the company still made good sales. Due to an earlier completion
of the overhaul, Guangji Mengzhou resumed its production in advance on August
27, 2019. Guangji Pharmaceutical is the largest producer of vitamin B2 across
the world, with a VB2 production capacity of 2,500 tonnes per year from Guangji
Mengzhou.
One-month suspension has little impact on
Guangji Pharmaceutical's revenue
According
to Guangji Pharmaceutical, the overhaul generally aimed at workshop equipment
of its subsidiary, Guangji Mengzhou. The company mainly engages itself in
production and sales regarding feed additives with import and export business,
especially vitamin B2.
It was
estimated that the related costs taking place during the overhaul accounted for
only 3.06% of the company’s annual production costs. In other words, the
company’s annual production costs were not affected to a great extent. Besides,
Guangji Pharmaceutical expressed that the suspension would not exert much
effect on the company’s revenue in 2019.
Guangji Pharmaceutical mainly produces raw
materials, medical preparations, and food and feed additives
Guangji
Pharmaceutical is a significant holding subsidiary belonging to Hubei
Changjiang Industrial Investment Group Co., Ltd. As a high-tech listed company
in China, Guangji Pharmaceutical mainly produces pharmaceutical raw materials, medical
preparations, and food and feed additives. Founded in 1969, the enterprise is
now integrated with scientific research and pharmaceutical production.
Most
importantly, Guangji Pharmaceutical becomes a large and powerful production
base of riboflavin in China. Its core production technology won the Second Prize
for Science & Technology Development in China and the First Prize for Science
& Technology Development in Hubei Province. One of the company’s products,
vitamin B2 for feed additives, was awarded honour of "China Famous Brand" in
2007.
Globally
speaking, the products of Guangji Pharmaceutical are exported from China to
more than 80 countries and regions. In terms of the sales volume of riboflavin,
Guangji Pharmaceutical is ranked among the leaders in the world.
Guangji Pharmaceutical, DSM, and BASF exceed
80% of the global vitamin B2 capacity
Vitamin B2
is one of the 13 essential vitamin elements of human body. It also plays an
important role in energy metabolism and material metabolism of organisms.
Animal
feeds and food additives serve as major demands of vitamin B2, representing
respectively 64% and 32% in the down-stream part of the demand structure. In
contrast, other uses like medicine are in less demand for Vitamin B2,
accounting for less than 5%. Internationally speaking, the overall demand for
vitamin B2 is around 7,000 tonnes in the market. In China, 2,000 tonnes of
vitamin B2 are demanded each year.
At present,
the overall production capacity of vitamin b2 gets to about 10,000 tonnes in
the world, among which 4,800 tonnes come from Guangji Pharmaceutical, 2,000
tonnes from DSM, and 1,500 tonnes from BASF. These three enterprises are the
leading ones in the vitamin B2 industry, with overall capacity of around 8,300
tonnes, exceeding 80% of the global capacity.
The main
vitamin B2 suppliers in China consist of Guangji Pharmaceutical and Haijianuo Pharmaceutical.
The subsidiary of Haijianuo Pharmaceutical, Inner Mongolia Chifeng Pharmaceutical
Co., Ltd., can produce 1,000 tonnes of vitamin B2 per year.
For more
information about China’s vitamin market, please have a look at our monthly
newsletter Vitamins
China E-News.